Literature DB >> 11753606

Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis.

R Gamberale1, J Geffner, G Arrosagaray, M Scolnik, G Salamone, A Trevani, M Vermeulen, M Giordano.   

Abstract

Malignant B cells from chronic lymphocytic leukemia (B-CLL) patients have a long survival in vivo, although, in culture, they spontaneously die by apoptosis. Here, we analyzed the capacity of accessory leukocytes to modulate apoptosis of B-CLL cells in vitro. To this end, we performed long-term cultures using total mononuclear cells (TMC) from B-CLL patients and TMC depleted from monocytes, NK cells and T lymphocytes (B-CLL cells). In all the patients studied (n = 25) the presence of accessory leukocytes markedly prolonged the survival of B-CLL cells. The anti-apoptotic effect was exerted by monocytes and, to a lesser degree, NK cells, partially through the release of soluble factors. Indeed, accessory leukocytes separated from leukemic cells by semipermeable membranes were still able to prolong B-CLL cell survival. By flow cytometric analysis we found that the protective effect of non-malignant cells was associated with delayed down-regulation of Bcl-2 expression on leukemic cells. By contrast, the expression of Fas and Fas ligand proteins was unchanged in most samples. Our findings suggest that monocytes and NK cells, by delaying leukemic cell apoptosis, may play a role in B-CLL cell accumulation in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753606     DOI: 10.1038/sj.leu.2402288

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

Authors:  Paula Fernández-Calotti; Marçal Pastor-Anglada
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

2.  The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.

Authors:  Pablo E Morande; Samanta R Zanetti; Mercedes Borge; Paula Nannini; Carolina Jancic; Raimundo F Bezares; Alicia Bitsmans; Miguel González; Andrea L Rodríguez; Carlos M Galmarini; Romina Gamberale; Mirta Giordano
Journal:  Invest New Drugs       Date:  2011-09-02       Impact factor: 3.850

3.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

4.  Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia.

Authors:  Marina Theodorou; Matthaios Speletas; Antigoni Mamara; Georgia Papachristopoulou; Vassiliki Lazou; Andreas Scorilas; Eleni Katsantoni
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

5.  A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro.

Authors:  Hussein Ghamlouch; Hakim Ouled-Haddou; Gandhi Damaj; Bruno Royer; Brigitte Gubler; Jean-Pierre Marolleau
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 6.  Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival.

Authors:  Nancy Nisticò; Domenico Maisano; Enrico Iaccino; Eleonora Vecchio; Giuseppe Fiume; Salvatore Rotundo; Ileana Quinto; Selena Mimmi
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.